Renowned physician executive and clinician-scientist joins BillionToOne to advance oncology medical strategy
MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are...
MENLO PARK, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are...
Northstar PGx™ and Northstar Select CH™ extend clinical insight and utility of Northstar Select ® all from the same blood-draw
BillionToOne Expands Its Leadership in Hemolytic Disease of the Fetus and Newborn (HDFN) and Extends Fetal Antigen Testing to Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
Integration enables seamless ordering and results delivery within Epic for UNITY Complete® and Northstar® tests, creating a better patient and provider experience
MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are...
Ultra-sensitive liquid biopsy is expanding precision medicine access for patients in Japan with treatment-resistant non-small cell lung cancer (NSCLC)
MENLO PARK, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are...